Overview

A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies

Status:
Withdrawn

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of JNJ-54452840 in participants with heart failure and anti-beta1-adrenergic receptor autoantibodies. The safety and tolerability of JNJ-54452840 will also be assessed.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Adrenergic Agents
Antibodies
Autoantibodies